Characterization of Key Bio–Nano Interactions between Organosilica Nanoparticles and Candida albicans
Nanoparticle–cell interactions between silica nanomaterials and mammalian cells have been investigated extensively in the context of drug delivery, diagnostics, and imaging. While there are also opportunities for applications in infectious disease, the interactions of silica nanoparticles with patho...
Gespeichert in:
Veröffentlicht in: | ACS applied materials & interfaces 2019-09, Vol.11 (38), p.34676-34687 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 34687 |
---|---|
container_issue | 38 |
container_start_page | 34676 |
container_title | ACS applied materials & interfaces |
container_volume | 11 |
creator | Kesarwani, Vidhishri Kelly, Hannah G Shankar, Madhu Robinson, Kye J Kent, Stephen J Traven, Ana Corrie, Simon R |
description | Nanoparticle–cell interactions between silica nanomaterials and mammalian cells have been investigated extensively in the context of drug delivery, diagnostics, and imaging. While there are also opportunities for applications in infectious disease, the interactions of silica nanoparticles with pathogenic microbes are relatively underexplored. To bridge this knowledge gap, here, we investigate the effects of organosilica nanoparticles of different sizes, concentrations, and surface coatings on surface association and viability of the major human fungal pathogen Candida albicans. We show that uncoated and PEGylated organosilica nanoparticles associate with C. albicans in a size and concentration-dependent manner, but on their own, do not elicit antifungal activity. The particles are also shown to associate with human white blood cells, in a similar trend as observed with C. albicans, and remain noncytotoxic toward neutrophils. Smaller particles are shown to have low association with C. albicans in comparison to other sized particles and their association with blood cells was also observed to be minimal. We further demonstrate that by chemically immobilizing the clinically important echinocandin class antifungal drug, caspofungin, to PEGylated nanoparticles, the cell–material interaction changes from benign to antifungal, inhibiting C. albicans growth when provided in high local concentration on a surface. Our study provides the foundation for defining how organosilica particles could be tailored for clinical applications against C. albicans. Possible future developments include designing biomaterials that could detect, prevent, or treat bloodstream C. albicans infections, which at present have very high patient mortality. |
doi_str_mv | 10.1021/acsami.9b10853 |
format | Article |
fullrecord | <record><control><sourceid>acs_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1021_acsami_9b10853</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>c949362287</sourcerecordid><originalsourceid>FETCH-LOGICAL-a330t-4bc364016ecfed9f3264a89d52016a56ca5a490b428202c3c7c6f76b1fc1b2ed3</originalsourceid><addsrcrecordid>eNp1kMtOwzAQRS0EoqWwZYm8RkrxK2myhIhHRUU3sI7Gjl1cpU5lp0JlxT_wh3wJrlK6YzMzmnvuaHQRuqRkTAmjN6ACrOy4kJTkKT9CQ1oIkeQsZceHWYgBOgthSUjGGUlP0YBTkfOioEO0KN_Bg-q0t5_Q2dbh1uBnvcV3tv35-n4B1-Kpi3Jkohqw1N2H1g7P_SJqwTZWAd5ha_CdVY0OGFyNy1hsDRgaGQEXztGJgSboi30fobeH-9fyKZnNH6fl7SwBzkmXCKl4JgjNtDK6LgxnmYC8qFMWd5BmClIQBZGC5YwwxdVEZWaSSWoUlUzXfITG_V3l2xC8NtXa2xX4bUVJtUus6hOr9olFw1VvWG_kStcH_C-iCFz3QDRWy3bjXfz_v2u_BVp4uA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Characterization of Key Bio–Nano Interactions between Organosilica Nanoparticles and Candida albicans</title><source>MEDLINE</source><source>American Chemical Society Journals</source><creator>Kesarwani, Vidhishri ; Kelly, Hannah G ; Shankar, Madhu ; Robinson, Kye J ; Kent, Stephen J ; Traven, Ana ; Corrie, Simon R</creator><creatorcontrib>Kesarwani, Vidhishri ; Kelly, Hannah G ; Shankar, Madhu ; Robinson, Kye J ; Kent, Stephen J ; Traven, Ana ; Corrie, Simon R</creatorcontrib><description>Nanoparticle–cell interactions between silica nanomaterials and mammalian cells have been investigated extensively in the context of drug delivery, diagnostics, and imaging. While there are also opportunities for applications in infectious disease, the interactions of silica nanoparticles with pathogenic microbes are relatively underexplored. To bridge this knowledge gap, here, we investigate the effects of organosilica nanoparticles of different sizes, concentrations, and surface coatings on surface association and viability of the major human fungal pathogen Candida albicans. We show that uncoated and PEGylated organosilica nanoparticles associate with C. albicans in a size and concentration-dependent manner, but on their own, do not elicit antifungal activity. The particles are also shown to associate with human white blood cells, in a similar trend as observed with C. albicans, and remain noncytotoxic toward neutrophils. Smaller particles are shown to have low association with C. albicans in comparison to other sized particles and their association with blood cells was also observed to be minimal. We further demonstrate that by chemically immobilizing the clinically important echinocandin class antifungal drug, caspofungin, to PEGylated nanoparticles, the cell–material interaction changes from benign to antifungal, inhibiting C. albicans growth when provided in high local concentration on a surface. Our study provides the foundation for defining how organosilica particles could be tailored for clinical applications against C. albicans. Possible future developments include designing biomaterials that could detect, prevent, or treat bloodstream C. albicans infections, which at present have very high patient mortality.</description><identifier>ISSN: 1944-8244</identifier><identifier>EISSN: 1944-8252</identifier><identifier>DOI: 10.1021/acsami.9b10853</identifier><identifier>PMID: 31483991</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Antifungal Agents - chemistry ; Antifungal Agents - pharmacology ; Candida albicans - growth & development ; Candidiasis - drug therapy ; Candidiasis - metabolism ; Candidiasis - pathology ; Coated Materials, Biocompatible - chemistry ; Coated Materials, Biocompatible - pharmacology ; Humans ; Nanoparticles - chemistry ; Nanoparticles - therapeutic use ; Neutrophils - metabolism ; Organosilicon Compounds - chemistry ; Organosilicon Compounds - pharmacology ; Polyethylene Glycols - chemistry ; Polyethylene Glycols - pharmacology</subject><ispartof>ACS applied materials & interfaces, 2019-09, Vol.11 (38), p.34676-34687</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a330t-4bc364016ecfed9f3264a89d52016a56ca5a490b428202c3c7c6f76b1fc1b2ed3</citedby><cites>FETCH-LOGICAL-a330t-4bc364016ecfed9f3264a89d52016a56ca5a490b428202c3c7c6f76b1fc1b2ed3</cites><orcidid>0000-0002-8539-4891 ; 0000-0001-8029-1896</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acsami.9b10853$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acsami.9b10853$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,780,784,2765,27076,27924,27925,56738,56788</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31483991$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kesarwani, Vidhishri</creatorcontrib><creatorcontrib>Kelly, Hannah G</creatorcontrib><creatorcontrib>Shankar, Madhu</creatorcontrib><creatorcontrib>Robinson, Kye J</creatorcontrib><creatorcontrib>Kent, Stephen J</creatorcontrib><creatorcontrib>Traven, Ana</creatorcontrib><creatorcontrib>Corrie, Simon R</creatorcontrib><title>Characterization of Key Bio–Nano Interactions between Organosilica Nanoparticles and Candida albicans</title><title>ACS applied materials & interfaces</title><addtitle>ACS Appl. Mater. Interfaces</addtitle><description>Nanoparticle–cell interactions between silica nanomaterials and mammalian cells have been investigated extensively in the context of drug delivery, diagnostics, and imaging. While there are also opportunities for applications in infectious disease, the interactions of silica nanoparticles with pathogenic microbes are relatively underexplored. To bridge this knowledge gap, here, we investigate the effects of organosilica nanoparticles of different sizes, concentrations, and surface coatings on surface association and viability of the major human fungal pathogen Candida albicans. We show that uncoated and PEGylated organosilica nanoparticles associate with C. albicans in a size and concentration-dependent manner, but on their own, do not elicit antifungal activity. The particles are also shown to associate with human white blood cells, in a similar trend as observed with C. albicans, and remain noncytotoxic toward neutrophils. Smaller particles are shown to have low association with C. albicans in comparison to other sized particles and their association with blood cells was also observed to be minimal. We further demonstrate that by chemically immobilizing the clinically important echinocandin class antifungal drug, caspofungin, to PEGylated nanoparticles, the cell–material interaction changes from benign to antifungal, inhibiting C. albicans growth when provided in high local concentration on a surface. Our study provides the foundation for defining how organosilica particles could be tailored for clinical applications against C. albicans. Possible future developments include designing biomaterials that could detect, prevent, or treat bloodstream C. albicans infections, which at present have very high patient mortality.</description><subject>Antifungal Agents - chemistry</subject><subject>Antifungal Agents - pharmacology</subject><subject>Candida albicans - growth & development</subject><subject>Candidiasis - drug therapy</subject><subject>Candidiasis - metabolism</subject><subject>Candidiasis - pathology</subject><subject>Coated Materials, Biocompatible - chemistry</subject><subject>Coated Materials, Biocompatible - pharmacology</subject><subject>Humans</subject><subject>Nanoparticles - chemistry</subject><subject>Nanoparticles - therapeutic use</subject><subject>Neutrophils - metabolism</subject><subject>Organosilicon Compounds - chemistry</subject><subject>Organosilicon Compounds - pharmacology</subject><subject>Polyethylene Glycols - chemistry</subject><subject>Polyethylene Glycols - pharmacology</subject><issn>1944-8244</issn><issn>1944-8252</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtOwzAQRS0EoqWwZYm8RkrxK2myhIhHRUU3sI7Gjl1cpU5lp0JlxT_wh3wJrlK6YzMzmnvuaHQRuqRkTAmjN6ACrOy4kJTkKT9CQ1oIkeQsZceHWYgBOgthSUjGGUlP0YBTkfOioEO0KN_Bg-q0t5_Q2dbh1uBnvcV3tv35-n4B1-Kpi3Jkohqw1N2H1g7P_SJqwTZWAd5ha_CdVY0OGFyNy1hsDRgaGQEXztGJgSboi30fobeH-9fyKZnNH6fl7SwBzkmXCKl4JgjNtDK6LgxnmYC8qFMWd5BmClIQBZGC5YwwxdVEZWaSSWoUlUzXfITG_V3l2xC8NtXa2xX4bUVJtUus6hOr9olFw1VvWG_kStcH_C-iCFz3QDRWy3bjXfz_v2u_BVp4uA</recordid><startdate>20190925</startdate><enddate>20190925</enddate><creator>Kesarwani, Vidhishri</creator><creator>Kelly, Hannah G</creator><creator>Shankar, Madhu</creator><creator>Robinson, Kye J</creator><creator>Kent, Stephen J</creator><creator>Traven, Ana</creator><creator>Corrie, Simon R</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-8539-4891</orcidid><orcidid>https://orcid.org/0000-0001-8029-1896</orcidid></search><sort><creationdate>20190925</creationdate><title>Characterization of Key Bio–Nano Interactions between Organosilica Nanoparticles and Candida albicans</title><author>Kesarwani, Vidhishri ; Kelly, Hannah G ; Shankar, Madhu ; Robinson, Kye J ; Kent, Stephen J ; Traven, Ana ; Corrie, Simon R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a330t-4bc364016ecfed9f3264a89d52016a56ca5a490b428202c3c7c6f76b1fc1b2ed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Antifungal Agents - chemistry</topic><topic>Antifungal Agents - pharmacology</topic><topic>Candida albicans - growth & development</topic><topic>Candidiasis - drug therapy</topic><topic>Candidiasis - metabolism</topic><topic>Candidiasis - pathology</topic><topic>Coated Materials, Biocompatible - chemistry</topic><topic>Coated Materials, Biocompatible - pharmacology</topic><topic>Humans</topic><topic>Nanoparticles - chemistry</topic><topic>Nanoparticles - therapeutic use</topic><topic>Neutrophils - metabolism</topic><topic>Organosilicon Compounds - chemistry</topic><topic>Organosilicon Compounds - pharmacology</topic><topic>Polyethylene Glycols - chemistry</topic><topic>Polyethylene Glycols - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kesarwani, Vidhishri</creatorcontrib><creatorcontrib>Kelly, Hannah G</creatorcontrib><creatorcontrib>Shankar, Madhu</creatorcontrib><creatorcontrib>Robinson, Kye J</creatorcontrib><creatorcontrib>Kent, Stephen J</creatorcontrib><creatorcontrib>Traven, Ana</creatorcontrib><creatorcontrib>Corrie, Simon R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>ACS applied materials & interfaces</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kesarwani, Vidhishri</au><au>Kelly, Hannah G</au><au>Shankar, Madhu</au><au>Robinson, Kye J</au><au>Kent, Stephen J</au><au>Traven, Ana</au><au>Corrie, Simon R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Characterization of Key Bio–Nano Interactions between Organosilica Nanoparticles and Candida albicans</atitle><jtitle>ACS applied materials & interfaces</jtitle><addtitle>ACS Appl. Mater. Interfaces</addtitle><date>2019-09-25</date><risdate>2019</risdate><volume>11</volume><issue>38</issue><spage>34676</spage><epage>34687</epage><pages>34676-34687</pages><issn>1944-8244</issn><eissn>1944-8252</eissn><abstract>Nanoparticle–cell interactions between silica nanomaterials and mammalian cells have been investigated extensively in the context of drug delivery, diagnostics, and imaging. While there are also opportunities for applications in infectious disease, the interactions of silica nanoparticles with pathogenic microbes are relatively underexplored. To bridge this knowledge gap, here, we investigate the effects of organosilica nanoparticles of different sizes, concentrations, and surface coatings on surface association and viability of the major human fungal pathogen Candida albicans. We show that uncoated and PEGylated organosilica nanoparticles associate with C. albicans in a size and concentration-dependent manner, but on their own, do not elicit antifungal activity. The particles are also shown to associate with human white blood cells, in a similar trend as observed with C. albicans, and remain noncytotoxic toward neutrophils. Smaller particles are shown to have low association with C. albicans in comparison to other sized particles and their association with blood cells was also observed to be minimal. We further demonstrate that by chemically immobilizing the clinically important echinocandin class antifungal drug, caspofungin, to PEGylated nanoparticles, the cell–material interaction changes from benign to antifungal, inhibiting C. albicans growth when provided in high local concentration on a surface. Our study provides the foundation for defining how organosilica particles could be tailored for clinical applications against C. albicans. Possible future developments include designing biomaterials that could detect, prevent, or treat bloodstream C. albicans infections, which at present have very high patient mortality.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>31483991</pmid><doi>10.1021/acsami.9b10853</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-8539-4891</orcidid><orcidid>https://orcid.org/0000-0001-8029-1896</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1944-8244 |
ispartof | ACS applied materials & interfaces, 2019-09, Vol.11 (38), p.34676-34687 |
issn | 1944-8244 1944-8252 |
language | eng |
recordid | cdi_crossref_primary_10_1021_acsami_9b10853 |
source | MEDLINE; American Chemical Society Journals |
subjects | Antifungal Agents - chemistry Antifungal Agents - pharmacology Candida albicans - growth & development Candidiasis - drug therapy Candidiasis - metabolism Candidiasis - pathology Coated Materials, Biocompatible - chemistry Coated Materials, Biocompatible - pharmacology Humans Nanoparticles - chemistry Nanoparticles - therapeutic use Neutrophils - metabolism Organosilicon Compounds - chemistry Organosilicon Compounds - pharmacology Polyethylene Glycols - chemistry Polyethylene Glycols - pharmacology |
title | Characterization of Key Bio–Nano Interactions between Organosilica Nanoparticles and Candida albicans |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T09%3A30%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-acs_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Characterization%20of%20Key%20Bio%E2%80%93Nano%20Interactions%20between%20Organosilica%20Nanoparticles%20and%20Candida%20albicans&rft.jtitle=ACS%20applied%20materials%20&%20interfaces&rft.au=Kesarwani,%20Vidhishri&rft.date=2019-09-25&rft.volume=11&rft.issue=38&rft.spage=34676&rft.epage=34687&rft.pages=34676-34687&rft.issn=1944-8244&rft.eissn=1944-8252&rft_id=info:doi/10.1021/acsami.9b10853&rft_dat=%3Cacs_cross%3Ec949362287%3C/acs_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31483991&rfr_iscdi=true |